Cargando…

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir

INTRODUCTION: Human immunodeficiency virus (HIV) infection and the long-term use of antiretroviral therapy, especially efavirenz (EFV)-based regimens, impact lipid profiles due to insulin resistance and lead to a higher risk of metabolic diseases. Dolutegravir (DTG) is an integrase inhibitor with be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khemla, Supphachoke, Meesing, Atibordee, Sribenjalux, Wantin, Chetchotisakd, Ploenchan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AboutScience 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158613/ https://www.ncbi.nlm.nih.gov/pubmed/37153647 http://dx.doi.org/10.33393/dti.2023.2529

Ejemplares similares

The comparative accuracy of pooled vs. individual blood culture sampling methods for diagnosis of catheter-related bloodstream infection
por: Deawtrakulchai, Phitphiboon, et al.
Publicado: (2022)

Insertion of a Clinical Pathway Pop-Up Window into a Computer-Based Prescription System: A Method to Promote Antibiotic Stewardship in Upper Respiratory Tract Infection
por: Sribenjalux, Wantin, et al.
Publicado: (2021)

The CREPE Score: A Predictive Tool for Third-Generation Cephalosporin-Resistant Enterobacterales Pneumonia in Community Settings
por: Khunkitti, Krisada, et al.
Publicado: (2023)

Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir
por: Keegan, Michael R., et al.
Publicado: (2018)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
por: Twimukye, Adelline, et al.
Publicado: (2021)

A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial
por: Anunnatsiri, Siriluck, et al.
Publicado: (2020)

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
por: Chan, Phillip, et al.
Publicado: (2022)

Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus
por: Desmonde, Sophie, et al.
Publicado: (2019)

1565. Lymphocyte Subsets as Predictors of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
por: Huang, Chang, et al.
Publicado: (2023)

1690. Risk Factors of Invasive Aspergillosis in Systemic Lupus Erythematosus Patients
por: Kunawathanakul, Sithichai, et al.
Publicado: (2019)

218. Development of a Simple Score for Diagnosis Melioidosis
por: Khaejawat, Kanjana, et al.
Publicado: (2023)

Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
por: Liu, Dafeng, et al.
Publicado: (2021)

Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023)

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa
por: Asare, Kwabena, et al.
Publicado: (2023)

1552. Absolute Lymphocyte Threshold: A Simple Readily Available Tool to Predict Risk of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

417. Factors associated with 30-day Mortality in Carbapenems-resistant Enterobacteriaceae Infections
por: Osaithai, Naphol, et al.
Publicado: (2022)

Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa
por: Brennan, Alana T., et al.
Publicado: (2023)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
por: Zash, Rebecca, et al.
Publicado: (2018)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
por: da Silva, Gabriella Jomara, et al.
Publicado: (2023)

Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection
por: So-ngern, Apichart, et al.
Publicado: (2023)

Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV
por: Ergen, Pınar, et al.
Publicado: (2022)

Diagnostic accuracy of a point‐of‐care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz‐based antiretroviral therapy
por: Dorward, Jienchi, et al.
Publicado: (2023)

Switch to dolutegravir is well tolerated in Thais with HIV infection
por: Goh, Orlanda Q, et al.
Publicado: (2019)

Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
por: Lee, Sang-Ah, et al.
Publicado: (2018)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

Effect of Abdominoplasty in the Lipid Profile of Patients with Dyslipidemia
por: Ramos-Gallardo, Guillermo, et al.
Publicado: (2013)

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
por: Jörimann, Lisa, et al.
Publicado: (2023)

Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
por: Belay, Yared Belete, et al.
Publicado: (2021)

Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells
por: George, Joseph W., et al.
Publicado: (2021)

A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China
por: Zhong, Mingli, et al.
Publicado: (2023)

The association of ESBL Escherichia coli with mortality in patients with Escherichia coli bacteremia at the emergency department
por: Phungoen, Pariwat, et al.
Publicado: (2022)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
por: Saple, Dattatray, et al.
Publicado: (2022)

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
por: Sinxadi, Phumla Zuleika, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_iqm3735g6njrqgf8elrq1v5rie